Low postseroconversion CD4 count and rapid decrease of CD4 density identify HIV+ fast progressors

AIDS Research and Human Retroviruses

Volumn 26, Issue 9, 2010, Pages 997-1005

  Audigé, Annette ^a   Taffé, Patrick ^b   Rickenbach, Martin ^b   Battegay, Manuel ^c   Vernazza, Pietro ^d   Nadal, David ^e   Speck, Roberto F ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^e UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL DENSITY; CELL LOSS; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MONOCYTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEROCONVERSION; BAYES THEOREM; BIOLOGICAL MODEL; HIV SEROPOSITIVITY; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY;

BAYES THEOREM; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; HIV; HIV SEROPOSITIVITY; HUMANS; MODELS, IMMUNOLOGICAL; RETROSPECTIVE STUDIES;

EID: 77956390977     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0263     Document Type: Article

References (43)

1. Konopka K and Duzgunes N: Expression of CD4 controls the susceptibility of THP-1 cells to infection by R5 and X4 HIV type 1 isolates. AIDS Res Hum Retroviruses 2002; 18(2):123-131.
2. Naif HM, Li S, Alali M, et al.: CCR5 expression correlates with susceptibility of maturing monocytes to human immunodeficiency virus type 1 infection. J Virol 1998;72(1): 830-836.
3. Pesenti E, Pastore C, Lillo F, Siccardi AG, Vercelli D, and Lopalco L: Role of CD4 and CCR5 levels in the susceptibility of primary macrophages to infection by CCR5-dependent HIV type 1 isolates. AIDS Res Hum Retroviruses 1999; 15(11):983-987.
4. Tuttle DL, Harrison JK, Anders C, Sleasman JW, and Goodenow MM: Expression of CCR5 increases during monocyte differentiation and directly mediates macrophage susceptibility to infection by human immunodeficiency virus type 1. J Virol 1998;72(6):4962-4969.
5. Wu L, Paxton WA, Kassam N, et al.: CCR5 levels and expression pattern correlate with infectability by macrophagetropic HIV-1, in vitro. J Exp Med 1997;185(9):1681-1691.
6. Walter BL, Wehrly K, Swanstrom R, Platt E, Kabat D, and Chesebro B: Role of low CD4 levels in the influence of human immunodeficiency virus type 1 envelope V1 and V2 regions on entry and spread in macrophages. J Virol 2005; 79(8):4828-4837.
7. Bannert N, Schenten D, Craig S, and Sodroski J: The level of CD4 expression limits infection of primary rhesus monkey macrophages by a T-tropic simian immunodeficiency virus and macrophagetropic human immunodeficiency viruses. J Virol 2000;74(23):10984-10993.
8. Vermeire K, Bell TW, Choi HJ, et al.: The anti-HIV potency of cyclotriazadisulfonamide analogs is directly correlated with their ability to down-modulate the CD4 receptor. Mol Pharmacol 2003;63(1):203-210.
9. Vermeire K, Princen K, Hatse S, et al.: CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro. AIDS 2004;18(16):2115-2125.
10. Vermeire K, Zhang Y, Princen K, et al.: CADA inhibits human immunodeficiency virus and human herpesvirus 7 replication by down-modulation of the cellular CD4 receptor. Virology 2002;302(2):342-353.
11. Alexander M, Bor YC, Ravichandran KS, Hammarskjold ML, and Rekosh D: Human immunodeficiency virus type 1 Nef associates with lipid rafts to downmodulate cell surface CD4 and class I major histocompatibility complex expression and to increase viral infectivity. J Virol 2004;78(4):1685-1696.
12. Glushakova S, Munch J, Carl S, et al.: Cd4 down-modulation by human immunodeficiency virus type 1 nef correlates with the efficiency of viral replication and with CD4(-) T-cell depletion in human lymphoid tissue ex vivo. J Virol 2001;75(21):10113-10117.
13. Lundquist CA, Tobiume M, Zhou J, Unutmaz D, and Aiken C: Nef-mediated downregulation of CD4 enhances human immunodeficiency virus type 1 replication in primary T lymphocytes. J Virol 2002;76(9):4625-4633.
14. Stoddart CA, Geleziunas R, Ferrell S, et al.: Human immunodeficiency virus type 1 Nef-mediated downregulation of CD4 correlates with Nef enhancement of viral pathogenesis. J Virol 2003;77(3):2124-2133.
15. Arganaraz ER, Schindler M, Kirchhoff F, Cortes MJ, and Lama J: Enhanced CD4 down-modulation by late stage HIV-1 nef alleles is associated with increased Env incorporation and viral replication. J Biol Chem 2003;278(36): 33912-33919.
16. Casartelli N, Di Matteo G, Argentini C, et al.: Structural defects and variations in the HIV-1 nef gene from rapid, slow and non-progressor children. AIDS 2003;17(9):1291-1301.
17. Casartelli N, Di Matteo G, Potesta M, Rossi P, and Doria M: CD4 and major histocompatibility complex class I downregulation by the human immunodeficiency virus type 1 nef protein in pediatric AIDS progression. J Virol 2003;77(21): 11536-11545.
18. Tobiume M, Takahoko M, Yamada T, Tatsumi M, Iwamoto A, and Matsuda M: Inefficient enhancement of viral infectivity and CD4 downregulation by human immunodeficiency virus type 1 Nef from Japanese long-term nonprogressors. J Virol 2002;76(12):5959-5965.
19. Lama J: The physiological relevance of CD4 receptor downmodulation during HIV infection. Curr HIV Res 2003;1(2):167-184.
20. Ginaldi L, De Martinis M, DOstilio A, Di Gennaro A, Marini L, and Quaglino D: Altered lymphocyte antigen expressions in HIV infection: A study by quantitative flow cytometry. Am J Clin Pathol 1997;108(5):585-592.
21. Nokta MA, Li XD, Nichols J, et al.: Chemokine/CD4 receptor density ratios correlate with HIV replication in lymph node and peripheral blood of HIV-infected individuals. AIDS 2001;15(2):161-169.
22. Poncelet P, Poinas G, Corbeau P, et al.: Surface CD4 density remains constant on lymphocytes of HIV-infected patients in the progression of disease. Res Immunol 1991;142(4):291-298.
23. Taffe P and May M: A joint back calculation model for the imputation of the date of HIV infection in a prevalent cohort. Stat Med 2008;27(23):4835-4853.
24. Diggle PK, Meixner MA, Carroll AB, and Aschwanden CF: Barriers to sexual reproduction in Polygonum viviparum: A comparative developmental analysis of P. viviparum and P. bistortoides. Ann Bot (Lond) 2002;89(2):145-156.
25. Evans BA, Feng Z, and Peterson AV: A comparison of generalized linear mixed model procedures with estimating equations for variance and covariance parameter estimation in longitudinal studies and group randomized trials. Stat Med 2001;20(22):3353-3373.
26. Mellors JW, Munoz A, Giorgi JV, et al.: Plasma viral load and CD4- lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126(12):946-954.
27. Mellors JW, Rinaldo CR, Jr., Gupta P, White RM, Todd JA, and Kingsley LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272(5265): 1167-1170.
28. Deeks SG, Kitchen CM, Liu L, et al.: Immune activation set point during early HIV infection predicts subsequent CD4- T-cell changes independent of viral load. Blood 2004; 104(4):942-947.
29. Hecht FM, Wang L, Collier A, et al.: A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis 2006;194(6):725-733.
30. Koegl C, Wolf E, Hanhoff N, et al.: Treatment during primary HIV infection does not lower viral set point but improves CD4 lymphocytes in an observational cohort. Eur J Med Res 2009;14(7):277-283.
31. Lee B, Sharron M, Montaner LJ, Weissman D, and Doms RW: Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci USA 1999;96(9):5215-5220.
32. Carcelain G, Debre P, and Autran B: Reconstitution of CD4- T lymphocytes in HIV-infected individuals following antiretroviral therapy. Curr Opin Immunol 2001;13(4):483-488.
33. Gazzola L, Tincati C, Bellistri GM, Monforte A, and Marchetti G: The absence of CD4- T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: Clinical risk, immunological gaps, and therapeutic options. Clin Infect Dis 2009;48(3):328-337.
34. Douek DC, Brenchley JM, Betts MR, et al.: HIV preferentially infects HIV-specific CD4- T cells. Nature 2002;417(6884): 95-98.
35. Haase AT: Population biology of HIV-1 infection: Viral and CD4- T cell demographics and dynamics in lymphatic tissues. Annu Rev Immunol 1999;17:625-656.
36. Haase AT, Henry K, Zupancic M, et al.: Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 1996;274(5289):985-989.
37. Lassen K, Han Y, Zhou Y, Siliciano J, and Siliciano RF: The multifactorial nature of HIV-1 latency. Trends Mol Med 2004;10(11):525-531.
38. Stacey AR, Norris PJ, Qin L, et al.: Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 2009;83(8):3719-3733.
39. Munier ML and Kelleher AD: Acutely dysregulated, chronically disabled by the enemy within: T-cell responses to HIV-1 infection. Immunol Cell Biol 2007;85(1):6-15.
40. Cruikshank WW, Kornfeld H, and Center DM: Interleukin-16. J Leukoc Biol 2000;67(6):757-766.
41. Center DM, Kornfeld H, Ryan TC, and Cruikshank WW: Interleukin 16: Implications for CD4 functions and HIV-1 progression. Immunol Today 2000;21(6):273-280.
42. Beaumier CM, Harris LD, Goldstein S, et al.: CD4 downregulation by memory CD4(-) T cells in vivo renders African green monkeys resistant to progressive SIVagm infection. Nat Med 2009;15(8):879-885.
43. Wu L: Biology of HIV mucosal transmission. Curr Opin HIV AIDS 2008;3(5):534-540.